Dr. Osinusi advocates for policies that encourage therapies to combat emerging viruses. This includes educating policymakers and administration officials on how intellectual property protections enabled the R&D that was so crucial to Gilead’s response to the COVID-19 pandemic. It also includes her work to explain how policies that undermine IP protections, like the TRIPS waiver, could impact the future development of antivirals and the ability to respond rapidly to pandemics.
Dr. Anu Osinusi
